Imunon Inc (IMNN) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Imunon Inc (IMNN) has a cash flow conversion efficiency ratio of -1.186x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-3.99 Million) by net assets ($3.36 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See IMNN defensive asset coverage days to measure how many days the company can operate on defensive assets alone.
Imunon Inc - Cash Flow Conversion Efficiency Trend (1996–2025)
This chart illustrates how Imunon Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Imunon Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Imunon Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
T4F Entretenimento S.A
SA:SHOW3
|
0.208x |
|
Augros Cosmetic Packaging SA
PA:AUGR
|
-0.287x |
|
Kibo Energy PLC
JSE:KBO
|
-0.011x |
|
UET United Electronic Technology AG
XETRA:CFC
|
8.013x |
|
Ho Hup Construction Company
KLSE:5169
|
0.003x |
|
E Media Holdings Ltd
JSE:EMH
|
0.047x |
|
Morella Corporation Ltd
AU:1MC
|
-0.082x |
|
Grolleau SAS
PA:ALGRO
|
0.045x |
Annual Cash Flow Conversion Efficiency for Imunon Inc (1996–2025)
The table below shows the annual cash flow conversion efficiency of Imunon Inc from 1996 to 2025. For the full company profile with market capitalisation and key ratios, see Imunon Inc market capitalisation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $7.06 Million | $-13.90 Million | -1.968x | +55.70% |
| 2024-12-31 | $4.24 Million | $-18.85 Million | -4.442x | -212.65% |
| 2023-12-31 | $13.39 Million | $-19.02 Million | -1.421x | -80.42% |
| 2022-12-31 | $29.33 Million | $-23.10 Million | -0.788x | -170.85% |
| 2021-12-31 | $55.80 Million | $-16.22 Million | -0.291x | +65.35% |
| 2020-12-31 | $18.61 Million | $-15.62 Million | -0.839x | +39.69% |
| 2019-12-31 | $14.56 Million | $-20.26 Million | -1.392x | -312.24% |
| 2018-12-31 | $20.86 Million | $-7.04 Million | -0.338x | +45.84% |
| 2017-12-31 | $26.70 Million | $-16.64 Million | -0.623x | +77.19% |
| 2016-12-31 | $6.73 Million | $-18.38 Million | -2.733x | -167.43% |
| 2015-12-31 | $20.39 Million | $-20.83 Million | -1.022x | -57.08% |
| 2014-12-31 | $32.83 Million | $-21.35 Million | -0.651x | -115.28% |
| 2013-12-31 | $31.52 Million | $-9.53 Million | -0.302x | +83.68% |
| 2012-12-31 | $11.96 Million | $-22.14 Million | -1.851x | -113.22% |
| 2011-12-31 | $26.19 Million | $-22.74 Million | -0.868x | -129.72% |
| 2010-12-31 | $-4.58 Million | $-13.37 Million | 2.921x | +3251.52% |
| 2009-12-31 | $10.04 Million | $-930.33K | -0.093x | -180.16% |
| 2008-12-31 | $19.73 Million | $2.28 Million | 0.116x | +136.99% |
| 2007-12-31 | $30.65 Million | $-9.58 Million | -0.313x | -113.84% |
| 2006-12-31 | $-3.20 Million | $-7.23 Million | 2.260x | +195.98% |
| 2005-12-31 | $3.43 Million | $-8.06 Million | -2.354x | -102.16% |
| 2004-12-31 | $11.97 Million | $-13.94 Million | -1.165x | -72.38% |
| 2003-12-31 | $13.45 Million | $-9.09 Million | -0.676x | +88.76% |
| 2002-12-31 | $1.52 Million | $-9.11 Million | -6.008x | -157.70% |
| 2001-12-31 | $2.67 Million | $-6.22 Million | -2.332x | -426.22% |
| 2000-12-31 | $8.73 Million | $-3.87 Million | -0.443x | +80.74% |
| 1999-12-31 | $1.00 Million | $-2.30 Million | -2.300x | -301.53% |
| 1998-12-31 | $-1.85 Million | $-2.11 Million | 1.141x | +143.19% |
| 1997-12-31 | $-2.46 Million | $-1.15 Million | 0.469x | +316.77% |
| 1996-12-31 | $6.76 Million | $-1.46 Million | -0.216x | -- |
About Imunon Inc
Imunon, Inc., a clinical-stage biotechnology company, focuses on developing immunotherapies and vaccines in the United States. The company's lead clinical program is IMNN-001, a DNA-based immunotherapy that is in a Phase 3 clinical trial for the localized treatment of advanced ovarian cancer, as well as in the IND-enabling phase for colorectal and pancreatic cancers, and in the discovery phase fo… Read more